Astrana Health (ASTH) Set to Announce Quarterly Earnings on Thursday

Key Points

• Astrana Health is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting $0.4573 in EPS and $1.02 billion in revenue.
• In the prior quarter, the company earned $0.80 per share, significantly exceeding estimates of $0.34, while revenue rose 48.5% year over year to $972.52 million but fell short of expectations.
• Wall Street maintains a “Moderate Buy” consensus, with eight Buy ratings and two Holds and an average price target of $49.88, versus the stock’s recent price of $36.67.

Astrana Health (NASDAQ:ASTH - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Astrana Health to post earnings of $0.4573 per share and revenue of $1.02 billion for the quarter. Individuals can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:30 PM ET.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.46. The business had revenue of $972.52 million during the quarter, compared to analyst estimates of $985.62 million. Astrana Health had a return on equity of 10.30% and a net margin of 1.05%. The company's revenue was up 48.5% on a year-over-year basis. During the same quarter last year, the business posted $0.19 EPS. On average, analysts expect Astrana Health to post $1.36 EPS for the current fiscal year and $1.93 EPS for the next fiscal year.

Astrana Health Stock Performance

Shares of ASTH stock opened at $36.67 on Thursday. The stock has a market cap of $2.04 billion, a PE ratio of 44.72 and a beta of 1.03. The business has a 50-day simple moving average of $37.19 and a 200-day simple moving average of $33.68. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 1.05. Astrana Health has a 52-week low of $18.08 and a 52-week high of $51.60.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. TD Cowen raised their target price on Astrana Health from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Barclays lifted their price target on Astrana Health from $50.00 to $53.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. BTIG Research boosted their price target on Astrana Health from $50.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Truist Financial upped their price objective on Astrana Health from $47.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Finally, Wall Street Zen cut shares of Astrana Health from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $49.88.

About Astrana Health

Astrana Health, Inc NASDAQ: ASTH, formerly known as Apollo Medical Holdings, is a healthcare enablement company focused on helping providers and health plans deliver coordinated, value-based care. The company combines physician networks, care-management capabilities, technology and data analytics to support improved clinical outcomes and more efficient healthcare delivery.

Astrana Health's services include population health management, physician practice support, utilization management, care coordination and clinical analytics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.